Key result
LMWH reaches ~39% of ICU days for VTE prophylaxis alongside persistent low-value albumin use.
Why the study?
This study sought to compare and contrast illustrative examples of adopting high value practices and de-adopting low value practices in intensive care units.
What are the current utilization rates, provider knowledge levels, and perceived barriers and facilitators for adopting LMWH for VTE prophylaxis and de-adopting albumin for fluid resuscitation in Canadian ICUs?
Observational (n=6,946)
Yes
What are the current utilization rates, provider knowledge levels, and perceived barriers and facilitators for adopting LMWH for VTE prophylaxis and de-adopting albumin for fluid resuscitation in Canadian ICUs?
Answers are grounded in this paper and cite their sources.
Despite high provider awareness and self-reported adherence to evidence, audit data revealed suboptimal adoption of LMWH for VTE prophylaxis and persistent use of low-value albumin resuscitation in Canadian ICUs, particularly in more severely ill patients.
OBJECTIVE: To compare and contrast illustrative examples of the adoption of high value practices and the de-adoption of low value practices. DESIGN: (1) Retrospective, population-based audit of low molecular weight heparin (LMWH) for venous thromboembolism (VTE) prophylaxis (high value practice) and albumin for fluid resuscitation (low value practice) and (2) cross-sectional survey of healthcare providers. SETTING: Data were collected from nine adult medical-surgical intensive care units (ICUs) in two large Canadian cities. Patients are managed in these ICUs by a group of multiprofessional and multidisciplinary healthcare providers. PARTICIPANTS: Participants included 6946 ICU admissions and 309 healthcare providers from the same ICUs. MAIN OUTCOME MEASURES: (1) The use of LMWH for VTE prophylaxis (per cent ICU days) and albumin for fluid resuscitation (per cent of patients); and (2) provider knowledge of evidence underpinning these practices, and barriers and facilitators to adopt and de-adopt these practices. RESULTS: LMWH was administered on 38.7% of ICU days, and 20.0% of patients received albumin.Most participants had knowledge of evidence underpinning VTE prophylaxis and fluid resuscitation (59.1% and 84.2%, respectively). Providers perceived these practices to be followed. The most commonly reported barrier to adoption was insufficient knowledge/understanding (32.8%), and to de-adoption was clinical leader preferences (33.2%). On-site education was the most commonly identified facilitator for adoption and de-adoption (67.8% and 68.6%, respectively). CONCLUSIONS: Despite knowledge of and self-reported adherence to best practices, the audit demonstrated opportunity to improve. Provider-reported barriers and facilitators to adoption and de-adoption are broadly similar.
No takes yet. Share an insight, caveat, or question.
Sauro et al. (2019) conducted an observational in Intensive care unit admission requiring VTE prophylaxis or fluid resuscitation (n=6,946). Adoption of low molecular weight heparin (LMWH) for VTE prophylaxis and de-adoption of albumin for fluid resuscitation vs. Unfractionated heparin (UFH) or mechanical VTE prophylaxis, and crystalloids for fluid resuscitation was evaluated on Use of LMWH for VTE prophylaxis (percent of ICU days) and use of albumin for fluid resuscitation (percent of patients). Low molecular weight heparin for VTE prophylaxis was administered on 38.7% of ICU days while 20.0% of eligible ICU admissions received low-value albumin fluid resuscitation.
Synapse has enriched 10 related papers. Consider them for comparative context: